N. Haddish-Berhane

发表

The role of multiscale computational approaches for rational design of conventional and nanoparticle oral drug delivery systems

Kamyar Haghighi, K. Haghighi, J. Rickus, 2007, International journal of nanomedicine.

Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approach

D. Ouellet, N. Haddish-Berhane, Hong Xie, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

N. Girard, R. Govindan, Keunchil Park, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies

M. Ahn, E. Cho, B. Cho, 2021, JTO clinical and research reports.

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

M. Ammirati, J. Treadway, S. Liras, 2011 .

A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate

J. Lucas, D. Shah, N. Haddish-Berhane, 2014, The AAPS Journal.

A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®

P. H. van der Graaf, D. Shah, Xiaoying Chen, 2019, The AAPS Journal.

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

D. Shah, N. Haddish-Berhane, A. Betts, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin

T. R. Johnson, P. Jasper, J. Tolsma, 2016, The AAPS Journal.

Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer.

S. Shreeve, Mikyung Kim, K. Yu, 2022, Lung cancer.

P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

M. Ahn, E. Cho, S. Shreeve, 2021 .

P76.73 MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC

S. Shreeve, K. Patel, J. Curtin, 2021 .

P15.03 A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-Mutated NSCLC

A. Roshak, R. Knoblauch, T. Hida, 2021 .

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

E. Cho, J. Infante, B. Cho, 2020 .

KRAS: Structure, function, and development of anticancer drugs

D. Parasrampuria, A. Yu, N. Haddish-Berhane, 2020 .

SIMDOT-AbMe: Microphysiologically Based Simulation Tool for Quantitative Prediction of Systemic and Local Bioavailability of Targeted Oral Delivery Formulations

A. Keshavarzian, K. Haghighi, A. Farhadi, 2009, Drug Metabolism and Disposition.

A multi-scale stochastic drug release model for polymer-coated targeted drug delivery systems.

O. Campanella, A. Keshavarzian, K. Haghighi, 2006, Journal of controlled release : official journal of the Controlled Release Society.

Biological variability and targeted delivery of therapeutics for inflammatory bowel diseases: an in silico approach.

A. Keshavarzian, K. Haghighi, A. Farhadi, 2007, Inflammation & Allergy - Drug Targets.

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

D. Shah, H. Barton, H. Gerber, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure

D. Ouellet, J. Jiao, J. Sukbuntherng, 2018, Cancer Chemotherapy and Pharmacology.

Establishing in vitro–in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach

Frank Loganzo, Tracey Clark, Dhaval K. Shah, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Mechanistic Projection of First‐in‐Human Dose for Bispecific Immunomodulatory P‐Cadherin LP‐DART: An Integrated PK/PD Modeling Approach

D. Xuan, P. Moore, H. Barton, 2016, Clinical pharmacology and therapeutics.

Antibody–drug conjugates: an emerging modality for the treatment of cancer

Mauricio Leal, Dhaval K Shah, A. Wahl, 2014, Annals of the New York Academy of Sciences.

Modeling film-coat non-uniformity in polymer coated pellets: a stochastic approach.

Kinam Park, Seong Hoon Jeong, Kamyar Haghighi, 2006, International journal of pharmaceutics.

Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology

T. Maurer, A. Ghosh, M. Leininger, 2011, The AAPS Journal.

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

R. Govindan, Keunchil Park, E. Cho, 2019, Journal of Clinical Oncology.

P76.74 PAPILLON: Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC

K. Patel, J. Curtin, A. Roshak, 2021 .

A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate

J. Lucas, D. Shah, N. Haddish-Berhane, 2014, The AAPS Journal.

A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®

P. H. van der Graaf, D. Shah, Xiaoying Chen, 2019, The AAPS Journal.

A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice

Justin Lucas, H. Gerber, C. May, 2018, Cancer Immunology, Immunotherapy.

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Jing Chen, David B Duignan, Robert Aiello, 2012, Journal of medicinal chemistry.

JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results.

E. Cho, K. Bae, E. Attiyeh, 2018, Annals of Oncology.

537MO First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers

J. Infante, I. Braña, V. Moreno, 2020 .

Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approach

D. Ouellet, N. Haddish-Berhane, Yue Guo, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation

J. Jiao, P. Hellemans, N. Haddish-Berhane, 2024, Clinical pharmacokinetics.

OA10.06 A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

M. Ahn, B. Cho, R. Knoblauch, 2018, Journal of Thoracic Oncology.